The Indian drug regulator has issued a stern warning to pharmaceutical companies not to promote prescription drugs used to treat obesity and metabolic disorders, especially GLP-1 receptor agonists, either directly or indirectly. They warned that doing so could break drug marketing rules.

The Central Drugs Standard Control Organization (CDSCO), which is part of the Directorate General of Health Services, sent out a notice to drug makers and importers reminding them that all drug promotion, distribution, and marketing must follow the rules set out in the Drugs and Cosmetics Act of 1940 and the Drugs Rules of 1945.

The regulator said it has received inputs suggesting that certain companies may be promoting obesity-related prescription medicines through surrogate channels such as disease awareness campaigns, digital outreach, and other indirect communication strategies that effectively create product visibility among the general public.

Such practices, the advisory clarified, could amount to misleading promotion if they directly or indirectly encourage the use of prescription medicines without appropriate medical supervision.

According to the regulator, prescription drugs, including GLP-1 receptor agonists, must only be prescribed by registered medical practitioners or specialists and should be promoted strictly in line with the approved indications and conditions of marketing authorisation.

The advisory specifically warned that any communication that exaggerates therapeutic benefits, promises guaranteed weight loss outcomes, or downplays the importance of lifestyle modifications such as diet control and physical activity may attract regulatory action.

Obesity, the regulator emphasised, is a chronic metabolic condition that requires comprehensive management, including behavioural and lifestyle interventions. Pharmacological therapy, where appropriate, must not be portrayed as a standalone or guaranteed solution for weight loss.

In a strong signal to the pharmaceutical marketing ecosystem, the regulator stated that even campaigns presented as public awareness initiatives could be treated as violations if they function as surrogate advertisements that generate brand recall or indirectly promote prescription medicines.

The advisory reiterated that the advertisement of prescription-only drugs to the general public is strictly prohibited across all platforms, including print, electronic, digital, and social media channels.

Pharmaceutical companies have also been instructed to ensure that Prescribing Information Sheets and Patient Information Leaflets clearly include details of authorised personnel and contact mechanisms for handling consumer queries and complaints.

The drug regulator has urged companies to send in detailed Risk Management Plans (RMPs) to help improve pharmacovigilance oversight. These plans should make sure that safety is always monitored and that steps are taken to reduce risks.

The CDSCO also reminded people who have marketing authorisations to respect ethical marketing rules and regulations so that vulnerable groups are not swayed by false claims or aggressive marketing methods.

The recommendation comes at a time when demand for weight-loss drugs is rising worldwide and in India. This is because more people are becoming aware of new drugs that can help them lose weight and because more people are becoming obese.

By reiterating existing regulatory provisions and tightening oversight on promotional practices, the regulator appears to be signalling a stricter enforcement environment for pharmaceutical companies marketing therapies in the rapidly expanding obesity treatment segment.

Drug manufacturers, importers, and marketing authorisation holders have been advised to strictly adhere to the advisory in the interest of public health and regulatory compliance.